BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27033979)

  • 1. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin.
    Connolly C; Magnusson-Lind A; Lu G; Wagner PK; Southwell AL; Hayden MR; Björkqvist M; Leavitt BR
    Neuroscience; 2016 Jun; 325():74-88. PubMed ID: 27033979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
    Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
    Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology.
    Savage JC; St-Pierre MK; Carrier M; El Hajj H; Novak SW; Sanchez MG; Cicchetti F; Tremblay MÈ
    J Neuroinflammation; 2020 Apr; 17(1):98. PubMed ID: 32241286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant huntingtin confers cell-autonomous phenotypes on Huntington's disease iPSC-derived microglia.
    Stöberl N; Donaldson J; Binda CS; McAllister B; Hall-Roberts H; Jones L; Massey TH; Allen ND
    Sci Rep; 2023 Nov; 13(1):20477. PubMed ID: 37993517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers.
    Politis M; Lahiri N; Niccolini F; Su P; Wu K; Giannetti P; Scahill RI; Turkheimer FE; Tabrizi SJ; Piccini P
    Neurobiol Dis; 2015 Nov; 83():115-21. PubMed ID: 26297319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin.
    Naia L; Ribeiro M; Rodrigues J; Duarte AI; Lopes C; Rosenstock TR; Hayden MR; Rego AC
    Neuropeptides; 2016 Aug; 58():73-81. PubMed ID: 26876526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease.
    Franciosi S; Ryu JK; Shim Y; Hill A; Connolly C; Hayden MR; McLarnon JG; Leavitt BR
    Neurobiol Dis; 2012 Jan; 45(1):438-49. PubMed ID: 21946335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.
    Silva AC; Ferreira IL; Hayden MR; Ferreiro E; Rego AC
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):34-44. PubMed ID: 28939435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice.
    Petkau TL; Hill A; Connolly C; Lu G; Wagner P; Kosior N; Blanco J; Leavitt BR
    Hum Mol Genet; 2019 May; 28(10):1661-1670. PubMed ID: 30624705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model.
    Johnson E; Chase K; McGowan S; Mondo E; Pfister E; Mick E; Friedline RH; Kim JK; Sapp E; DiFiglia M; Aronin N
    J Huntingtons Dis; 2015; 4(3):219-229. PubMed ID: 26444021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
    Donley DW; Realing M; Gigley JP; Fox JH
    PLoS One; 2021; 16(5):e0250606. PubMed ID: 33989290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naïve Huntington's disease microglia mount a normal response to inflammatory stimuli but display a partially impaired development of innate immune tolerance that can be counteracted by ganglioside GM1.
    Steinberg N; Galleguillos D; Zaidi A; Horkey M; Sipione S
    J Neuroinflammation; 2023 Nov; 20(1):276. PubMed ID: 37996924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.
    Crotti A; Benner C; Kerman BE; Gosselin D; Lagier-Tourenne C; Zuccato C; Cattaneo E; Gage FH; Cleveland DW; Glass CK
    Nat Neurosci; 2014 Apr; 17(4):513-21. PubMed ID: 24584051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
    Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
    Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired Replenishment of Cortico-Striatal Synaptic Glutamate in Huntington's Disease Mouse Model.
    Buren C; Tu G; Raymond LA
    J Huntingtons Dis; 2020; 9(2):149-161. PubMed ID: 32310183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease.
    Casaca-Carreira J; Toonen LJA; Evers MM; Jahanshahi A; van-Roon-Mom WMC; Temel Y
    Biomed Pharmacother; 2016 Dec; 84():93-96. PubMed ID: 27639545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
    Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
    Chang R; Liu X; Li S; Li XJ
    Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.
    Björkqvist M; Wild EJ; Thiele J; Silvestroni A; Andre R; Lahiri N; Raibon E; Lee RV; Benn CL; Soulet D; Magnusson A; Woodman B; Landles C; Pouladi MA; Hayden MR; Khalili-Shirazi A; Lowdell MW; Brundin P; Bates GP; Leavitt BR; Möller T; Tabrizi SJ
    J Exp Med; 2008 Aug; 205(8):1869-77. PubMed ID: 18625748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.